CLAIMS:

1. A composition for nasal delivery comprising zolpidem or a pharmaceutically acceptable salt thereof.

2. The composition according to claim 1 in the form of a solution or a powder.

3. The composition according to claim 2 in the form of an aqueous solution.

4. The composition according to claim 1, comprising a salt of zolpidem selected from the hydrochloride, mesilate, citrate, nitrate, lactate, maleate, tartrate, phosphate, succinate, fumarate and gluconate salts.

5. The composition according to claim 4, wherein the salt is the tartrate salt.

6. The composition according to claim 1, which is in the form of a solution and comprising from 0.8 to 97 mg/ml of zolpidem (expressed as the free base).

7. The composition according to claim 6, comprising from 24 to 80 mg/ml of zolpidem (expressed as the free base).

8. The composition according to claim 6, comprising from 2.4 to 16 mg/ml of zolpidem (expressed as the free base).

9. The composition according to claim 1, in the form of a solution and comprising a solubility enhancing agent.

10. The composition according to claim 9, wherein the solubility enhancing agent is a cyclodextrin.

11. The composition according to claim 10, wherein the cyclodextrin is sulfobutylether-β-cyclodextrin (SBE-CD).

12. The composition according to claim 11, comprising 50 to 700 mg/ml SBE-CD.

13. The composition according to claim 1, having a pH of from 3.0 to 8.0.

14. The composition according to claim 1, additionally comprising chitosan, a salt, a derivative thereof or a salt of a derivative thereof.

15. The composition according to claim 14, comprising from 0.5 to 50 mg/ml of chitosan, a salt, a derivative thereof or a salt of a derivative thereof.

16. The composition according to claim 1, which is an aqueous solution and comprises from 30 to 60 mg/ml of zolpidem tartrate, 100 to 300 mg/ml SBE-CD and 2 to 10 mg/ml of chitosan glutamate.

17. The composition according to claim 1, which is an aqueous solution and comprises from 3 to 20 mg/ml of zolpidem tartrate and 2 to 10 mg/ml of chitosan glutamate.

18. The composition according to claim 1, in the form of a non-aqueous solution.

19. The composition according to claim 18, comprising at least one of ethanol, propylene glycol, polyethylene glycol, glycofurol, benzyl benzoate and a polyoxyethylene castor oil derivative.

20. The composition according to claim 1, in the form of a powder.

21. The composition according to claim 20, wherein the powder contains granules or microspheres.

22. The composition according to claim 20, comprising 20 to 70 % by weight of zolpidem (expressed as free base).

23. The composition according to claim 20, further comprising a means for improving the rate of dissolution of zolpidem in the nasal cavity.

24. The composition according to claim 23, wherein the means is a cyclodextrin.

25. The composition according to claim 24, wherein the ratio by weight of zolpidem or a pharmaceutically acceptable thereof to cyclodextrin is from 1:0.25 to 1:10.

26. The composition according to claim 24, wherein the cyclodextrin is sulfobutylether-β-cyclodextrin (SBE-CD).

27. The composition according to claim 20, further comprising chitosan, a salt, a derivative thereof or a salt of a derivative thereof.

28. The composition according to claim 27, comprising from 5 to 50 % by weight of chitosan, a salt, a derivative thereof or a salt of a derivative thereof.

29. The use of zolpidem or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for nasal administration to a patient in need thereof.

30. The use according to claim 29 in the manufacture of a medicament for the treatment or prevention of insomnia or for the treatment of a neurological disorder or for the treatment of Parkinson's disease.

31. The use according to claim 30, wherein the neurological disorder is one arising from brain trauma, stroke or spinocerebellar ataxia.

32. A method of administering zolpidem or a pharmaceutically acceptable salt thereof to a patient in need thereof, which method comprise the intranasal administration of a composition as defined in claim 1.

33. A method of treating or preventing insomnia, which method comprises the intranasal administration of a composition as defined in claim 1.

34. A method of treating a neurological disorder or Parkinson's disease, which method comprises the intranasal administration of a composition as defined in claim 1.

35. A method according to claim 34, wherein the neurological disorder is one arising from brain trauma, stroke or spinocerebellar ataxia.

36. A nasal drug delivery device or a dose cartridge for use in a nasal drug delivery device comprising a composition as defined in claim 1.